Market Access NHS to offer Wegovy to a million more people in England PharmaphorumThe NHS in England will make Novo Nordisk's Wegovy available to around 1.2m people in order to reduce their risk of heart attacks and strokes.Market AccessMetabolic & GLP-1Read full story pharminent April 1, 2026 (Last updated: April 1, 2026) Pharmaphorum The NHS in England will make Novo Nordisk’s Wegovy available to around 1.2m people in order to reduce their risk of heart attacks and strokes. Market AccessMetabolic & GLP-1Read full story Post navigation Previous: S16 Ep43: FDA Approval Insights: Rucaparib for BRCA Mutation-Associated mCRPC: With David Morris, MD, FACS; and Alan H. Bryce, MDNext: ACC 2026: Tonlamarsen lowers angiotensinogen without extra BP benefit Related Stories Market Access Deal finally unlocks NHS access to ITF’s Duchenne drug pharminent May 11, 2026 Market Access Specialty Pharmacy Accreditation: DCI’s Exclusive Analysis Reveals a Market at an Inflection Point pharminent May 5, 2026 Market Access Where Gross-to-net Pressure Actually Lives After Launch pharminent May 1, 2026
